S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
The single greatest medical breakthrough of all time? (Ad)
Canadian autoworkers ratify new labor agreement with Ford
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
The single greatest medical breakthrough of all time? (Ad)
Canadian autoworkers ratify new labor agreement with Ford
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
The single greatest medical breakthrough of all time? (Ad)
Canadian autoworkers ratify new labor agreement with Ford
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
The single greatest medical breakthrough of all time? (Ad)
Canadian autoworkers ratify new labor agreement with Ford
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
NASDAQ:CSTL

Castle Biosciences (CSTL) Stock Forecast, Price & News

$16.52
-0.14 (-0.84%)
(As of 09/22/2023 08:51 PM ET)
Compare
Today's Range
$16.37
$16.91
50-Day Range
$15.30
$19.93
52-Week Range
$9.26
$30.08
Volume
102,400 shs
Average Volume
397,997 shs
Market Capitalization
$442.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.29

Castle Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
95.4% Upside
$32.29 Price Target
Short Interest
Healthy
2.67% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.15mentions of Castle Biosciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$1.37 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.68) to ($3.13) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

Medical Sector

259th out of 962 stocks

Medical Laboratories Industry

6th out of 23 stocks


CSTL stock logo

About Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

CSTL Price History

CSTL Stock News Headlines

Castle Scales Higher on Industry Award
Fraud Expert: Dump these three popular stocks
A major (and legal) market manipulation scheme is about to play out. It could cost you a fortune – or double your money. You choose. Find out what he knows, here.
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Castle Biosciences (NASDAQ: CSTL)
Castle Biosciences Reports Second Quarter 2023 Results
Why Castle Biosciences Stock Is Jumping Today
Castle Biosciences's Earnings: A Preview
BTIG Remains a Buy on Castle Biosciences (CSTL)
Why Shares of Castle Biosciences Fell This Week
BTIG Sticks to Its Buy Rating for Castle Biosciences (CSTL)
See More Headlines
Receive CSTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Castle Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CSTL Company Calendar

Last Earnings
8/02/2023
Today
9/25/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CSTL
Fax
N/A
Employees
582
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$32.29
High Stock Price Forecast
$41.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+95.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-67,140,000.00
Pretax Margin
-52.98%

Debt

Sales & Book Value

Annual Sales
$137.04 million
Book Value
$15.15 per share

Miscellaneous

Free Float
24,746,000
Market Cap
$442.90 million
Optionable
Not Optionable
Beta
0.81
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Derek J. MaetzoldMr. Derek J. Maetzold (Age 61)
    Founder, CEO, Pres & Director
    Comp: $1.45M
  • Mr. Frank StokesMr. Frank Stokes (Age 53)
    CFO & Treasurer
    Comp: $849.36k
  • Ms. Kristen M. Oelschlager R.N.Ms. Kristen M. Oelschlager R.N. (Age 55)
    RN, Chief Operating Officer
    Comp: $782.7k
  • Mr. Tobin W. Juvenal (Age 63)
    Chief Commercial Officer
    Comp: $782.7k
  • Camilla Zuckero
    VP of Investor Relations & Corp. Affairs
  • Ms. Alice Bahner Izzo
    Sr. VP of Marketing
  • Ms. Keli Greenberg
    VP of HR & Exec. Director of HR
  • Dr. Robert W. Cook Ph.D. (Age 51)
    Sr. VP of R&D
  • Mr. Bernhard E. SpiessMr. Bernhard E. Spiess (Age 63)
    Company Sec.













CSTL Stock - Frequently Asked Questions

Should I buy or sell Castle Biosciences stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Castle Biosciences in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CSTL shares.
View CSTL analyst ratings
or view top-rated stocks.

What is Castle Biosciences' stock price forecast for 2023?

4 analysts have issued 1-year target prices for Castle Biosciences' shares. Their CSTL share price forecasts range from $25.00 to $41.00. On average, they expect the company's share price to reach $32.29 in the next year. This suggests a possible upside of 95.4% from the stock's current price.
View analysts price targets for CSTL
or view top-rated stocks among Wall Street analysts.

How have CSTL shares performed in 2023?

Castle Biosciences' stock was trading at $23.54 on January 1st, 2023. Since then, CSTL shares have decreased by 29.8% and is now trading at $16.52.
View the best growth stocks for 2023 here
.

When is Castle Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our CSTL earnings forecast
.

How were Castle Biosciences' earnings last quarter?

Castle Biosciences, Inc. (NASDAQ:CSTL) announced its quarterly earnings data on Wednesday, August, 2nd. The company reported ($0.70) EPS for the quarter, beating analysts' consensus estimates of ($1.01) by $0.31. The company earned $50.14 million during the quarter, compared to the consensus estimate of $43.51 million. Castle Biosciences had a negative net margin of 53.04% and a negative trailing twelve-month return on equity of 22.57%.

What ETF holds Castle Biosciences' stock ?

First Trust Nasdaq Lux Digital Health Solutions ETF holds 98 shares of CSTL stock, representing 0.21% of its portfolio.

What other stocks do shareholders of Castle Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Castle Biosciences investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), DexCom (DXCM), QUALCOMM (QCOM), Teladoc Health (TDOC), Applied Materials (AMAT), Incyte (INCY) and Intel (INTC).

When did Castle Biosciences IPO?

(CSTL) raised $50 million in an IPO on Thursday, July 25th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. SVB Leerink and Baird acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

What is Castle Biosciences' stock symbol?

Castle Biosciences trades on the NASDAQ under the ticker symbol "CSTL."

Who are Castle Biosciences' major shareholders?

Castle Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (11.51%), Granahan Investment Management LLC (9.43%), BlackRock Inc. (7.95%), Principal Financial Group Inc. (5.07%), Bellevue Group AG (4.19%) and Palisade Capital Management LP (2.25%). Insiders that own company stock include Adam Jay Sussman, Bernhard E Spiess, Daniel Bradbury, David S Kabakoff, Derek J Maetzold, Derek J Maetzold, Ellen Goldberg, Frank Stokes, Jeffrey E Eberwein, Joseph C Cook III, Kristen M Oelschlager, Mara G Aspinall, Tiffany Olson and Tobin W Juvenal.
View institutional ownership trends
.

How do I buy shares of Castle Biosciences?

Shares of CSTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Castle Biosciences' stock price today?

One share of CSTL stock can currently be purchased for approximately $16.52.

How much money does Castle Biosciences make?

Castle Biosciences (NASDAQ:CSTL) has a market capitalization of $442.90 million and generates $137.04 million in revenue each year. The company earns $-67,140,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis.

How many employees does Castle Biosciences have?

The company employs 582 workers across the globe.

How can I contact Castle Biosciences?

Castle Biosciences' mailing address is 820 S FRIENDSWOOD DRIVE SUITE 201, FRIENDSWOOD TX, 77546. The official website for the company is castlebiosciences.com. The company can be reached via phone at (866) 788-9007 or via email at ir@castlebiosciences.com.

This page (NASDAQ:CSTL) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -